On November 11, Jinshi Data News, HaiLi Bio announced that the company plans to sell 76.07% of the equity of Yangling Jinhai held by its controlling shareholder, Shanghai Haoyuan. After the completion of this transaction, the company will no longer directly hold the equity of Yangling Jinhai, and Yangling Jinhai will no longer be included in the company’s consolidated financial statements; and the company will recover all loans to Yangling Jinhai and repay the relevant bank loans.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Haili Biology: Intends to sell 76.07% equity of Yangling Jinhai to its controlling shareholder Shanghai Haoyuan
On November 11, Jinshi Data News, HaiLi Bio announced that the company plans to sell 76.07% of the equity of Yangling Jinhai held by its controlling shareholder, Shanghai Haoyuan. After the completion of this transaction, the company will no longer directly hold the equity of Yangling Jinhai, and Yangling Jinhai will no longer be included in the company’s consolidated financial statements; and the company will recover all loans to Yangling Jinhai and repay the relevant bank loans.